Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights. Security and Exchange Commission SEC Sangamo Therapeutics, Inc Form 10-Q SEC.report. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and its Current Report on Form 8-Kas filed with the … Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highli ... in Sangamo's Annual Report … 2018 Q2. Sangamo Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). SANGAMO THERAPEUTICS, INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SANGAMO THERAPEUTICS, INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. F: 781-575-2152www.computershare.com, © Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, or     therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurodegenerative diseases. ST-920 gene therapy for Fabry disease and TX200 CAR-Treg cell therapy, in the clinic, and will work closely with our collaborator, Kite, as they advance KITE-037, an anti-CD19 allogeneic CAR-T therapy into a Phase 1/2 clinical trial. Sangamo Therapeutics, Inc Form 8-K. Companies; Documents; Forms; Alerts; Stock Ticker Lookup. For a more detailed discussion of these and other risks, please see Sangamo’s SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Amendments to Articles of Incorporation or Bylaws. One such company is Sangamo Therapeutics (NASDAQ:SGMO), with a market cap of $987 million. Six US sites are currently active and screening subjects for the Phase 1/2 STAAR study evaluating ]]> Sangamo BioSciences does not currently have any hardcopy reports on AnnualReports.com. Minimum 15 minutes delayed. It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. About Sangamo Therapeutics ... including its most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q. The company was founded in 1995 in Richmond, California. 8-K. Departure of Directors or Certain Officers. PART I. data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII levels following treatment with SB-525 through to 44 weeks, the Sangamo Therapeutics, Inc Form 10-K. Companies; Documents; Forms; Alerts; Stock Ticker Lookup. by the newly announced Biogen collaboration, and will continue to look for additional synergistic partnership opportunities to advance our mission to bring innovative genomic medicines to patients and to create value for our shareholders.”. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of … Sangamo Therapeutics, Sangamo Corporate Presentation January 2021, 39th Annual J.P. Morgan Healthcare Conference, Barclays Gene Editing & Gene Therapy Summit, 29th Annual Credit Suisse Virtual Healthcare Conference, Sangamo Third Quarter 2020 Teleconference Call, Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer, Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee, Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference, Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy. Sangamo Therapeutics, ... 8-K, 10K, Annual Reports) filed by Sangamo Therapeutics, Inc. Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Received Orphan Drug Designation from the European Medicines Agency for Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of … These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law. View all. Sangamo Therapeutics, Inc. share prices are not performing particularly well compared to other companies within the same industry. Find the latest Sangamo Therapeutics, Inc. (SGMO) stock quote, history, news and other vital information to help you with your stock trading and investing. Sangamo Therapeutics Inc. //-->2010&&document.write(new Date().getFullYear()); Corporate Communications Pfizer is currently enrolling patients in a 6-month 2016 Annual Report Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - … United States (HSR). 10-Q. 8-K. Sangamo Therapeutics Reports … Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Yahoo 11/04 17:45 ET -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Posts Q3 … Financial statements and reports for Sangamo Therapeutics Inc Com Stk USD0.01 including annual reports and financial results for the last 5 years. These risks and uncertainties are described more fully in Sangamo’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission and Sangamo’s Annual Report on Form 10-K that it intends to file shortly. The The Investor Relations website contains information about Sangamo Therapeutics, … Sangamo Therapeutics, Inc. assumes no obligation to update the forward-looking information contained in this press release. 6 Jan 21. Sangamo’s robust and diverse pipeline of genomic medicines in clinical and preclinical stages of development encompass a breadth of distinct but complementary technical approaches. Diff. Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. Meet the Sangamo Therapeutics Management Team. 'This quarter marked an important milestone for Sangamo, as we transitioned to a Phase 3 company following the transfer of the IND for SB-525 hemophilia A gene therapy to our partner Pfizer, … Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of … Sangamo Therapeutics, Inc. share prices are not performing particularly well compared to other companies within the same industry. On December 7, 2020, Sangamo Therapeutics, Inc. (“Sangamo”) issued a joint press release (the “Press Release”) with Pfizer Inc. (“Pfizer”) announcing updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for patients with severe hemophilia A (the “Alta Study”). Forward-looking statements contained in this announcement are made as of this date, and Sangamo … SANGAMO THERAPEUTICS, INC. Form 10-K (Filer) Published: 2020-02-28 16:53:03 Submitted: 2020-02-28 Filing Agent: Period Ending In: 2019-12-31 Interactive … Tabl e of Contents. SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, Conference Call and Webcast Scheduled for 8 a.m. Eastern Time. including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target. ST-920, an investigational gene therapy candidate for Fabry disease. 2018 Q3. Data Provided by Refinitiv. Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. Form 10-K Sangamo Therapeutics, Inc Annual report [Section 13 and 15(d), not S-K Item 405] SEC.report. Forward-looking statements contained in this announcement are made as of this date, and Sangamo … Sangamo Therapeutics, Inc. assumes no obligation to update the forward-looking information contained in this press release. Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST. Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Dec 7, 2020 Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy Sangamo, as we transitioned to a Phase III company following the transfer of the IND for SB-525 hemophilia A gene therapy to our partner Pfizer, who plan to commence the registrational study this year. RICHMOND, Calif., May 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported first quarter 2018 financial results and recent accomplishments. For a more detailed discussion of these and other risks, please see Sangamo’s SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. 250 Royall Street Diff. We will also continue to advance new IND targets in highly prevalent diseases, as exemplified Aron Feingold Brisbane, California, February 28, 2020 – Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today Phase 3 lead-in study, which serves as the foundation of the Phase 3 registrational study. As is evident from the statistics, the company’s shares have risen +22.27 percent over the past six months and at a 7.06% annual growth rate that is well below the industry average of 14.3%. 8-K. Other Events. Forward-looking statements contained in this announcement are made as of this date, and Sangamo … 15 Dec 20. Current reports. About Sangamo Therapeutics ... including its most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. For financial reporting, their fiscal year ends on December 31st. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law. Click the button below to request a report when hardcopies become available. SB-525 gene therapy in hemophilia A to development partner Pfizer, triggering a $25 million milestone payment. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission and Sangamo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 that it intends to file this week. 8 Nov 18. Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation. As is evident from the statistics, the company’s shares have risen +22.27 percent over the past six months and at a 7.06% annual growth rate that is well below the industry average of 14.3%. 8-K. 10-Q. Diff. Under the terms of the collaboration, Biogen has exclusive global rights to ST-501 for tauopathies View all SGMO assets, cash, debt, liabilities, shareholder equity and investments. Annual balance sheet by MarketWatch. • the benefits of the acquisition of Sangamo Therapeutics France S.A.S., ... which speak only as of the date of this Annual Report on Form 10-K. 3. Annual report. Sangamo Therapeutics, Inc. (the “Company”) is filing this Amendment No. Yesterday, announced global collaboration agreement with Biogen to develop and commercialize gene regulation These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission and Sangamo's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 that it filed August 7, 2019. Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. The company's product … Meet the leaders and learn more about Sangamo's latest developments. The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. BRISBANE, Calif., Feb. 28, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2018 financial results and recent business highlights. 7 Dec 20. This page shows recent SEC filings related to Sangamo BioSciences, Inc. [CDATA[// >